Skip to main content
. 2013 Nov 7;19(1):357–366. doi: 10.2119/molmed.2013.00099

Figure 3.

Figure 3

HMGB1-TLR4 signaling mediates liver I/R injury. HMGB1 is an early mediator of injury and inflammation in liver I/R, and TLR4 is the major receptor that is involved in the process by which the JNK MAPK/NF-κB pathway is activated. The release of HMGB1 in liver I/R requires TLR4 but not CD14. Different strategies of HMGB1-TLR4 pathway inhibition as indicated have been shown to reduce liver I/R injury.